130 related articles for article (PubMed ID: 12377638)
21. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Fang Y; Wang L; Xia GH; Shi MQ
Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
[TBL] [Abstract][Full Text] [Related]
22. Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter?
Di Maio M; Bria E; Rossi A; Perrone F
Ann Oncol; 2008 Feb; 19(2):402-3. PubMed ID: 18180243
[No Abstract] [Full Text] [Related]
23. A Phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly.
Chen YM; Perng RP; Tsai CM; Whang-Peng J
J Thorac Oncol; 2006 Feb; 1(2):141-5. PubMed ID: 17409843
[TBL] [Abstract][Full Text] [Related]
24. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed.
Azzoli CG; Kris MG; Pfister DG
J Natl Cancer Inst; 2007 Jun; 99(11):828-9. PubMed ID: 17551137
[No Abstract] [Full Text] [Related]
26. European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.
Novello S; Le Chevalier T
Semin Oncol; 2001 Aug; 28(4 Suppl 14):3-9. PubMed ID: 11605176
[TBL] [Abstract][Full Text] [Related]
27. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
[TBL] [Abstract][Full Text] [Related]
28. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
D'Addario G; Pintilie M; Leighl NB; Feld R; Cerny T; Shepherd FA
J Clin Oncol; 2005 May; 23(13):2926-36. PubMed ID: 15728229
[TBL] [Abstract][Full Text] [Related]
29. Oxaliplatin doublets in non-small cell lung cancer: a literature review.
Cortinovis D; Bidoli P; Zilembo N; Fusi A; Bajetta E
Lung Cancer; 2008 Jun; 60(3):325-31. PubMed ID: 18440088
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
Belani CP;
Semin Oncol; 2002 Jun; 29(3 Suppl 12):4-9. PubMed ID: 12170445
[TBL] [Abstract][Full Text] [Related]
32. Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials.
Tyagi P
Clin Lung Cancer; 2005 Jul; 7(1):17-9. PubMed ID: 16098239
[No Abstract] [Full Text] [Related]
33. Paclitaxel and docetaxel combinations in non-small cell lung cancer.
Belani CP
Chest; 2000 Apr; 117(4 Suppl 1):144S-151S. PubMed ID: 10777470
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
Belani CP; Lee JS; Socinski MA; Robert F; Waterhouse D; Rowland K; Ansari R; Lilenbaum R; Natale RB
Ann Oncol; 2005 Jul; 16(7):1069-75. PubMed ID: 15860487
[TBL] [Abstract][Full Text] [Related]
35. NSCLC--platinum or not.
Androulakis N; Georgoulias V
Lung Cancer; 2005 Mar; 47(3):381-3. PubMed ID: 15713521
[No Abstract] [Full Text] [Related]
36. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
Besse B; Le Chevalier T
J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
[No Abstract] [Full Text] [Related]
37. Targeted therapy for non-small-cell lung cancer.
Rasul KI; Al-Khater AM
J R Coll Physicians Edinb; 2010 Sep; 40(3):221. PubMed ID: 21127765
[No Abstract] [Full Text] [Related]
38. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.
Rossi A; Di Maio M; Chiodini P; Rudd RM; Okamoto H; Skarlos DV; Früh M; Qian W; Tamura T; Samantas E; Shibata T; Perrone F; Gallo C; Gridelli C; Martelli O; Lee SM
J Clin Oncol; 2012 May; 30(14):1692-8. PubMed ID: 22473169
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel poliglumex/carboplatin is similar to paclitaxel/carboplatin as first-line treatment in elderly patients with advanced non-small-cell lung cancer and a poor performance status.
Reddy GK
Clin Lung Cancer; 2005 Jul; 7(1):20-2. PubMed ID: 16098240
[No Abstract] [Full Text] [Related]
40. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Belani C;
Semin Oncol; 2001 Jun; 28(3 Suppl 9):10-4. PubMed ID: 11441409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
